Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell Lymphoma
Condition(s):Angioimmunoblastic T-cell LymphomaLast Updated:January 5, 2022Not yet recruiting
Hide Studies Not Open or Pending
Condition(s):Angioimmunoblastic T-cell LymphomaLast Updated:January 5, 2022Not yet recruiting
Condition(s):Relapsed Angioimmunoblastic T-Cell Lymphoma; Refractory Angioimmunoblastic T-cell LymphomaLast Updated:January 30, 2024Recruiting
Condition(s):Angioimmunoblastic T-cell LymphomaLast Updated:April 20, 2022Active, not recruiting
Condition(s):Angioimmunoblastic T-cell LymphomaLast Updated:September 25, 2017Unknown status
Condition(s):LymphomaLast Updated:June 29, 2023Terminated
Condition(s):Solid Tumor; Glioma; Angioimmunoblastic T-cell Lymphoma; Intrahepatic Cholangiocarcinoma; ChondrosarcomaLast Updated:February 23, 2021Completed
Condition(s):LymphomaLast Updated:August 26, 2013Unknown status
Condition(s):Angioimmunoblastic T-cell LymphomaLast Updated:January 25, 2024Recruiting
Condition(s):LymphomaLast Updated:October 14, 2020Terminated
Condition(s):Angioimmunoblastic T-cell LymphomaLast Updated:April 5, 2021Unknown status
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.